Netupitant - Palonosetron FDC Market to Expand due to Increased Prevalence of Cancer and Consequent Rise in CINV Patient Pool

Vomiting and nausea are the two basic side effects related to cancer chemotherapy, and are called as chemotherapy induced nausea and vomiting (CINV). Numerous sources report that around 70% to 80% patients of cancer taking chemotherapy treatment show major symptoms of vomiting and nausea. Chemotherapy induced vomiting and nausea is a tremendously debilitating condition. There are presently a variety of drugs accessible to manage CINV. The fixed dose combination (FDC) of netupitant as well as palonosetron is a product projected for the treatment of these side effects of chemotherapy.The global market for CINV drugs was estimated at US$1.28 billion in 2013, is expanding at a CAGR of 5.7% between 2014 and 2020, and is predicted to reach US$1.88 billion by 2020.

Get Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=729

Netupitant-Palonosetron FDC: Promising Trial Results Helping Market Expansion

Netupitant-Palonosetron FDC market is presently in its trialing third stage.  Netupitant is a selective and novel NK1 receptor antagonist; additionally, palonosetron is a clinically discrete and second-generation 5-HT3 receptor antagonist. Even though netupitant has never been in the drug market before, palonosetron drugs are readily available under the trade names Onicit, Paloxi, and Aloxi. The combination drug is predicted to trounce the key problems related to the present mode of treatment pertaining to the CINV condition, which involves the utilization of 5-HT3 receptor antagonists.

The FDC combination of palonosetron and netupitant has demonstrated proficient results in Phase II of clinical trials. It is being predicted that demand for this drug will be experiencing a boost as patient and physician preference would move towards enhanced treatment methods for CINV.  The increased prevalence of a variety of cancers and the consequent rise in the patient pool suffering from CINV is expected to be the key reason behind the development of the global CINV market. Just like Emend, Netupitant-Palonosetron FDC will have a significant patient pool ready following its launch in 2014.

North America: Largest Regional Market for CINV Drugs in 2013

On the basis of geography, the global CINV drugs market is segmented into North America, Asia Pacific, Europe, and RoW. On the basis of revenue, North America was the biggest regional market in 2013 for CINV drugs and is anticipated to hold its position through the forecast period. In 2013, Europe registered the second biggest market for CINV drugs after North America. In Europe, the introduction of CINV drugs is predicted to be a year later than its introduction in North America, because of the delays in the past launches of CINV drugs such as Emend and Aloxi. The high occurrence of numerous types of cancers in Asia Pacific as well as the Rest of the World (RoW) has led to both these regions emerging as budding markets for CINV drugs.The leading companies that manufacture Netupitant - Palonosetron FDC include Helsinn Group, GlaxoSmithKline plc, Heron Therapeutics, Inc., Tesaro, Inc., and Merck & Co., Inc.

Browse Full Global Netupitant - Palonosetron FDC Market Report With Complete TOC @ http://www.transparencymarketresearch.com/netupitant-palonosetron-fdc-market.html

About Us: 
Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact:

Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
United States.
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Blog: http://www.tmrblog.com/